ATE329600T1 - Verwendung von tagatose zur verbesserung wichtiger blutfaktoren - Google Patents

Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Info

Publication number
ATE329600T1
ATE329600T1 AT00921648T AT00921648T ATE329600T1 AT E329600 T1 ATE329600 T1 AT E329600T1 AT 00921648 T AT00921648 T AT 00921648T AT 00921648 T AT00921648 T AT 00921648T AT E329600 T1 ATE329600 T1 AT E329600T1
Authority
AT
Austria
Prior art keywords
tagatose
blood factors
important blood
improve important
improve
Prior art date
Application number
AT00921648T
Other languages
English (en)
Inventor
Gilbert Levin
Original Assignee
Biospherics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biospherics Inc filed Critical Biospherics Inc
Application granted granted Critical
Publication of ATE329600T1 publication Critical patent/ATE329600T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00921648T 1999-04-26 2000-04-04 Verwendung von tagatose zur verbesserung wichtiger blutfaktoren ATE329600T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/299,023 US6015793A (en) 1999-04-26 1999-04-26 Use of tagatose to enhance key blood factors

Publications (1)

Publication Number Publication Date
ATE329600T1 true ATE329600T1 (de) 2006-07-15

Family

ID=23152990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921648T ATE329600T1 (de) 1999-04-26 2000-04-04 Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Country Status (7)

Country Link
US (1) US6015793A (de)
EP (1) EP1173186B1 (de)
JP (1) JP2002542294A (de)
AT (1) ATE329600T1 (de)
AU (1) AU4193800A (de)
DE (1) DE60028750T2 (de)
WO (1) WO2000064451A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058710A1 (en) * 2001-01-25 2002-08-01 University Of Maryland, Baltimore Tagatose as a novel treatment for metabolic syndrome x, dyslipidemia, and coronary artery disease
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent
US20060286248A1 (en) * 2003-10-02 2006-12-21 Anfinsen Jon R Reduced-carbohydrate and nutritionally-enhanced frozen desserts and other food products
JP2012506912A (ja) * 2008-11-04 2012-03-22 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション アテローム硬化症、メタボリックシンドロームおよびそれらの症状を予防および処置するためのｄ−タガトースベースの組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786722A (en) * 1986-08-29 1988-11-22 Biospherics Incorporated D-tagatose as a low-calorie carbohydrate sweetener and bulking agent
CA2077257C (en) * 1989-07-19 2002-02-19 James R. Beadle Process for manufacturing tagatose
US5002612A (en) * 1989-07-19 1991-03-26 Biospherics Incorporated Process for manufacturing tagatose
US5356879A (en) * 1992-02-14 1994-10-18 Biospherics, Incorporated D-tagatose as anti-hyperglycemic agent

Also Published As

Publication number Publication date
EP1173186B1 (de) 2006-06-14
JP2002542294A (ja) 2002-12-10
DE60028750T2 (de) 2007-02-08
EP1173186A4 (de) 2004-07-14
US6015793A (en) 2000-01-18
DE60028750D1 (de) 2006-07-27
EP1173186A1 (de) 2002-01-23
AU4193800A (en) 2000-11-10
WO2000064451A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE474052T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
ATE249421T1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
BG108492A (bg) Използване на въглероден окис за подобряване на резултатите при трансплантация на тъкани и органи и потискане на апоптозата
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
EA199801044A1 (ru) Модуляторы регенерации тканей
ATE476990T1 (de) Cd20-bindende polypeptidzusammensetzungen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
PT1083903E (pt) Indenopirrolocarbazoles em ponte
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
ATE68977T1 (de) Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.
EP1098642A4 (de) Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
HUP0100668A2 (hu) Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk
DK1329461T3 (da) Fremgangsmåde til fjernelse af humane serum-albumin-polymerer
ATE300295T1 (de) Verwendung von baclofen zur behandlung von alkoholismus
DE69840637D1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
DE50002119D1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties